For a 13th consecutive year, The Blood and Marrow Transplant (BMT) Program at Northside Hospital Cancer Institute has been recognized as having among the very best survival outcomes in the United States for bone marrow transplants. No other transplant program in the country has achieved this milestone.
The data was provided by the Centers for International Blood and Marrow Transplant Research (CIBMTR) in their Final 2021 Transplant Center Survival Report, which tabulated patient survival following transplantation at 173 adult and pediatric transplant centers in the U.S.
Patients who received their first allogeneic transplant between January 1, 2017 and December 31, 2019 using unrelated or related donors were analyzed. Each center’s survival was compared to risk-adjusted average national survival data and then statistically designated as either superior to, matching or inferior to expectations.
The one-year survival of patients transplanted at the BMT Program at Northside was 80.8%. Northside is the only center in Georgia to achieve outcomes statistically superior to expectations and is one of only 15 centers in the U.S. to achieve this status for the current 2021 reporting cycle. Northside also is the only center in the U.S. to achieve superior outcomes for the past 13 consecutive annual reporting cycles.
"This unmatched result of 13 consecutive years of survival outcomes that exceed expectations on the national standardized comparison of transplant centers is an astonishing achievement for Northside Hospital and for Georgia, and is an indication that patients receive the very best transplant care here,” said Dr Asad Bashey, director of clinical research for the BMT Program at Northside.
“The BMT Program at Northside Hospital is the largest allogeneic transplant center in Georgia,” added Dr. Bashey. “However, success is not just a result of our size, but of the level of expertise of our clinical teams, our dedicated state-of-the-art facilities, and the innovative policies and procedures at our center that are focused singularly at providing the very best results possible following transplantation.”
The BMT Program at Northside is one of the largest and most comprehensive programs of its kind in the Southeast. The Program is among select centers in the country offering FDA-approved commercial and clinical research chimeric antigen receptor CAR T-cell therapy, one of the most promising cellular-based cancer immunotherapies available. Northside also has pioneered the use of outpatient management even for the most complex transplant procedures and the safe use of alternative donors when conventional donors may not be available.